
AI is about to change healthcare. These 7 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Xero, you need to believe in its ability to turn product innovation, especially AI and payments, into durable subscriber and ARPU growth while managing rising costs and competition. Meltzer’s appointment strengthens execution capacity in the US but does not fundamentally change the near term catalyst around monetizing new AI and payments products, nor the key risk that higher acquisition and hiring costs outpace revenue growth.
The recent launch of online bill payments in the US through Melio is the most relevant backdrop for Meltzer’s move. His experience across QuickBooks, Google, and LegalZoom sits squarely against this catalyst, as Xero works to deepen adoption of integrated accounting and payments among US small businesses and advisors, where success or disappointment could quickly influence revenue growth trends and perceptions of Xero’s US opportunity.
But while US expansion sounds attractive, investors should be aware that rising customer acquisition and hiring costs could...
Read the full narrative on Xero (it's free!)
Xero's narrative projects NZ$5.2 billion revenue and NZ$643.1 million earnings by 2029.
Uncover how Xero's forecasts yield a A$129.29 fair value, a 69% upside to its current price.
The most optimistic analysts were already assuming Xero could lift revenue about 29 percent a year and push earnings toward NZ$975.9 million, so Meltzer’s US remit may either support that faster international expansion story or highlight just how uncertain those growth and margin expectations really are.
Explore 8 other fair value estimates on Xero - why the stock might be worth over 2x more than the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com